Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males
Abstract
Abstract Background Guidelines recommend fluoroquinolones or cotrimoxazole for urinary tract infections in men (UTIm), but safety data in frail older patients remain limited. The aim of this study was to compare the tolerability of these antibiotics in UTIm patients over age 75 years. Methods This multicenter retrospective study included patients age ≥75 years who were hospitalized for UTIm in 8 hospitals and treated with oral fluoroquinolone or cotrimoxazole. Adverse events (AEs) during hospitalization were compared. Results Among 228 patients (median age, 85 years), 131 (57.4%) received fluoroquinolones and 97 (42.6%) cotrimoxazole. Baseline characteristics were similar. AEs occurred in 29.7% of fluoroquinolone-treated patients vs 48.5% treated with cotrimoxazole (P = .006), leading to treatment discontinuation in 2.3% vs 11.3% (P = .009). Acute kidney injury was observed in 7.2% vs 29.4% (P < .001), metabolic disorders in 7.6% vs 18.6% (P = .023). Other AEs and mortality did not differ significantly. Cotrimoxazole was associated with a doubled risk of AEs (adjusted odds ratio, 2.10; 95% CI, 1.18–3.74; P = .01). Conclusions These results suggest a better safety profile of fluoroquinolones than cotrimoxazole in the treatment of UTI in older men. These results need to be confirmed in a prospective design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.